Background: Since 2015, docetaxel chemotherapy, combined with ADT, is considered the standard of care in fit men with metastatic hormone-naive prostate cancer (m-HNPC), based on data from three phase III trials (GETUG-AFU 15, CHAARTED, and STAMPEDE). No data are currently available regarding the treatments used beyond progression after upfront ADT and docetaxel. Methods: We retrospectively collected data from patients (pts) participating in the GETUG-AFU 15 phase III trial concerning treatments received beyond progression for castration-resistant disease (CRPC) in both arms (ADT and ADT + docetaxel) including treatment efficacy (measured by a PSA decline > 50%, physician assessment of clinical benefit, and time to events), and toxicity (NCI-CTC grading). Results: Data concerning 164 pts are currently available. The treatments most frequently used and their efficacy are detailed in the Table. Toxicity was mild, with only rare grade 3-4 events (16% with first treatments and 13% with second treatments used for CRPC) and no treatment-related death. Conclusions: In this retrospective analysis, anticancer activity was suggested with androgen receptor axis-targeted agents in patients with metastatic prostate cancer treated upfront with ADT + docetaxel. Rather limited activity was observed following a docetaxel rechallenge in this setting.